Influence of primary tumor location and resection on survival in metastatic colorectal cancer

Tharin, Zoé; Blanc, Julie; Alaoui, Ikram Charifi; Bertaut, Aurélie; Ghiringhelli, François

doi:10.4251/wjgo.v12.i11.1296

Cited by 13 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study demonstrates that even those mCRC patients with unresectable metastases can have survival advantage bene t from left-sided SC plus BT treatment strategy. Our result is con icted with the ndings reported in a recent retrospective analysis [29]. In Tharin's study, the use of oxaliplatin, EGFR inhibitors, or bevacizumab did not bene t patients with unresectable metastases for both left and right sided mCRC patients [29].…”

Section: Discussionsupporting

confidence: 85%

“…Our result is con icted with the ndings reported in a recent retrospective analysis [29]. In Tharin's study, the use of oxaliplatin, EGFR inhibitors, or bevacizumab did not bene t patients with unresectable metastases for both left and right sided mCRC patients [29]. However, Tharin's study evaluated different types of BT than our study which might explain the variation in the results.…”

Section: Discussionsupporting

confidence: 82%

“…Most mCRC patients who did not perform primary tumor recession were having unresectable lesions or they are intolerant to surgery [29,30]. Thus, mCRC patients with no primary tumor recession might start their systemic chemotherapy earlier than mCRC with decided primary tumor recession [30].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Primary Tumor Location and Survival Among Metastatic Colorectal Cancer Patients treated with systemic chemotherapy, and biologic therapies: Retrospective Analysis (2013-2016)

Ramadan

Alfayea²,

Alsofyani

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: In a sample of Middle Eastern population, we sought to evaluate whether survival outcomes for mCRC patients treated with systemic chemotherapy (SC) and, with and without biologic therapies (bevacizumab and cetuximab) are different between left and right-sided tumors. Methods: Ministry of National Guard- Health Affairs (MNG-HA) Cancer registry data was utilized to identify patients diagnosed with CRC between 2013 and 2016. Kaplan-Meier method and porosity score adjusted Cox proportional hazard models were used to assess survival for right and left-sided mCRC with and with BT. Results: A total of 196 mCRC patients with mean age of 64 years old, 57.65% male diagnosed from January 1, 2013, through December 31, 2016. The overall median survival for left-sided was significantly higher than right-sided mCRC tumors (P 0.03). mCRC patients treated with SC+BT were associated with decreased mortality only among patients with left-sided mCRC compared to right-sided mCRC (HR, 0.21; 95% CI, 0.05-0.92; P .03). mCRC with no primary-tumor resection and CS+TB left-sided mCRC was significantly associated with decreased mortality compared to right-sided mCRC (HR, 0.15; 95% CI, 0.03-0.72; P .02).Conclusions: In a sample of Middle Eastern population, a significant decrease in mortality for left-sided mCRC treated with SC plus BT compared with right-sided mCRC was observed. mCRC patients with unresectable metastases demonstrated survival benefit from left-sided SC plus BT treatment. Randomized controlled trials are needed to determine the optimal treatment for mCRC patients.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Primary Tumor Location and Survival Among Metastatic Colorectal Cancer Patients treated with systemic chemotherapy, and biologic therapies: Retrospective Analysis (2013-2016)

Ramadan

Alfayea²,

Alsofyani

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Breast tumors, or tumors in breast tissue, can be divided into primary and metastatic according to their origin [ 1 , 2 ]. In general, LGG has a benign tendency, well differentiated, and better prognosis, while HGG is a low differentiated and aggressive malignant tumor [ 3 , 4 ]. Currently, the morbidity and mortality of breast tumors are increasing year by year.…”

Section: Introductionmentioning

confidence: 99%

Tumor Region Location and Classification Based on Fuzzy Logic and Region Merging Image Segmentation Algorithm

Zhao

Dai

2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Early diagnosis of tumor plays an important role in the improvement of treatment and survival rate of patients. However, breast tumors are difficult to be diagnosed by invasive examination, so medical imaging has become the most intuitive auxiliary method for breast tumor diagnosis. Although there is no universal perfect method for image segmentation so far, the consensus on the general law of image segmentation has produced considerable research results and methods. In this context, this paper focuses on the breast tumor image segmentation method based on CNN and proposes an improved DCNN method combined with CRF. This method can obtain the information of multiscale and pixels better. The experimental results show that, compared with DCNN without these methods, the segmentation accuracy is significantly improved.

show abstract

“…It is now well established that primary tumor location (PTL) is a major prognostic factor in mCRC, right-sided mCRC's having a poorer prognosis than left-sided mCRCs (13)(14)(15). The prognosis of rectal cancers, is similar to the prognosis of left-sided CRCs (16). To our knowledge, there is no data exploring the PFS rates according to the first line of chemotherapy and depending on PTL.…”

Section: Introductionmentioning

confidence: 99%

Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer

Tharin¹,

Blanc²,

Alaoui³

et al. 2021

J Gastrointest Oncol

Self Cite

View full text Add to dashboard Cite

Background: Primary tumor location (PTL) is a major prognostic factor in metastatic colorectal cancer (mCRC) with left side which present better prognosis than right sided. Uncertainty exists regarding comparative effectiveness of irinotecan or oxaliplatin doublet in mCRC in function of PTL. Methods: We conducted a retrospective comparing clinical outcomes from both regimens in function of sidedness. Patients with newly diagnosed mCRC candidates to first-line chemotherapy were selected. Clinical outcomes were assessed and stratified by tumor location (left, right and rectal) and type of treatment. Results: Overall, 702 patients met the inclusion criteria. Primary colon cancer was right-sided in 248 (35.3%) patients, left-sided in 296 (42.2%) and rectal in 158 (22.5%) patients. Whatever PTL monochemotherapy give poor progression-free survival (PFS) and overall survival (OS). Triplet give better PFS and OS only for rectal cancer. When looking at doublet in first line. Folinic acid, 5FU, and irinotecan (FOLFIRI) give better PFS in rectal cancer [PFS of 21.2 (95% CI: 14.9-NR) versus 12.2 (95% CI: 10.1-13.4) months for the folinic acid, 5FU, and oxaliplatin (FOLFOX) group, P=0.009] and at trend for better PFS in right side tumor [14.9 (95% CI: 8.8-20.8) versus 11.3 (95% CI: 8.4-13.2) months for the FOLFOX group. P=0.0755]. No difference was observed in term of OS.Conclusions: our results support that either FOLFIRI or FOLFOX regimens give similar efficacy in both left and right metastatic colic cancer. FOLFIRI and FOLFIRINOX regimens might be preferred for metastatic rectal carcinoma.

show abstract

Influence of primary tumor location and resection on survival in metastatic colorectal cancer

Cited by 13 publications

References 17 publications

Primary Tumor Location and Survival Among Metastatic Colorectal Cancer Patients treated with systemic chemotherapy, and biologic therapies: Retrospective Analysis (2013-2016)

Primary Tumor Location and Survival Among Metastatic Colorectal Cancer Patients treated with systemic chemotherapy, and biologic therapies: Retrospective Analysis (2013-2016)

Tumor Region Location and Classification Based on Fuzzy Logic and Region Merging Image Segmentation Algorithm

Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer

Contact Info

Product

Resources

About